Watch: Interview with IRBM’s Heidi Kingdon Jones By Jim Cornall 1 minutemin December 20, 2022 1 minutemin Share WhatsApp Twitter Linkedin Email Photo/Labiotech Newsletter Signup - Under Article / In Page"*" indicates required fieldsNameThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* The IRBM Group is an innovative research and discovery CRO (contract research organization) working across all aspects of drug discovery and early development. Headquartered in Italy, the company fosters collaborations with organizations from the pharma, biotech, non-profit and academic sectors to accelerate the development of vaccines and medicines. About 250 scientists work at the company’s R&D facility near Rome, where projects are carried out under one roof, enabling rapid cycle times and close integration of the scientific teams. IRBM’s scientists have discovered several marketed therapeutics, and more than 25 molecules have progressed into clinical testing.We spoke with IRBM’s global vice president of sales and marketing, Heidi Kingdon Jones, at Bio-Europe, which was held in Leipzig, Germany.How AI and LLMs are helping chemists design drugs faster and smarter This webinar explores how AI is reshaping medicinal chemistry. See how large language models (LLMs) and agentic workflows help chemists accelerate design, uncover new ideas, and make faster, more informed decisions in drug discovery. Register now Explore other topics: Drug developmentDrug discoveryItaly ADVERTISEMENT